Avalyn Pharma Inc.
AVLN
$38.71
$2.135.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | -28.94M | -26.87M | -20.19M | ||
| Total Depreciation and Amortization | 110.00K | 63.00K | 9.00K | ||
| Total Amortization of Deferred Charges | 17.00K | 5.00K | -- | ||
| Total Other Non-Cash Items | 2.72M | 1.07M | 657.00K | ||
| Change in Net Operating Assets | 10.00K | -4.16M | -1.17M | ||
| Cash from Operations | -26.08M | -29.89M | -20.70M | ||
| Capital Expenditure | -269.00K | -318.00K | 0.00 | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -118.44M | 55.34M | -36.69M | ||
| Cash from Investing | -118.71M | 55.02M | -36.69M | ||
| Total Debt Issued | 0.00 | 15.00M | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | 320.85M | 25.00K | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | 89.88M | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -4.18M | -163.00K | -- | ||
| Cash from Financing | 316.67M | 14.86M | 89.88M | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 171.89M | 40.00M | 32.50M | ||